tiprankstipranks
Advertisement
Advertisement

XENE Stock Latest News

Xenon’s Azetukalner: Rapid, Durable Efficacy and Once‑Daily Convenience Underpin Buy Rating and Preferred Second‑Line Epilepsy Positioning
RatingsXenon’s Azetukalner: Rapid, Durable Efficacy and Once‑Daily Convenience Underpin Buy Rating and Preferred Second‑Line Epilepsy Positioning
6d ago
XENE
Xenon Pharmaceuticals presents data from Phase 3 X-TOLE2 study
PremiumThe Fly
Xenon Pharmaceuticals presents data from Phase 3 X-TOLE2 study
7d ago
XENE
Xenon to Spotlight Neurology Pipeline at Series of 2026 Investor Conferences
PremiumCompany Announcements
Xenon to Spotlight Neurology Pipeline at Series of 2026 Investor Conferences
11d ago
XENE
Xenon Expands 2025 Inducement Equity Incentive Plan
PremiumCompany Announcements
Xenon Expands 2025 Inducement Equity Incentive Plan
13d ago
8K
XENE
Xenon to Unveil Phase 3 Azetukalner Data and Pipeline Advances at 2026 AAN Meeting
PremiumCompany Announcements
Xenon to Unveil Phase 3 Azetukalner Data and Pipeline Advances at 2026 AAN Meeting
19d ago
XENE
Xenon Pharmaceuticals price target lowered to $63 from $64 at Wedbush
PremiumThe FlyXenon Pharmaceuticals price target lowered to $63 from $64 at Wedbush
1M ago
XENE
Xenon Sets Date for 2026 Annual Shareholder Meeting
Premium
Company Announcements
Xenon Sets Date for 2026 Annual Shareholder Meeting
1M ago
8K
XENE
Xenon’s X-TOLE2 Trial Completion Puts XEN1101 in Focus for Epilepsy Investors
Premium
Company Announcements
Xenon’s X-TOLE2 Trial Completion Puts XEN1101 in Focus for Epilepsy Investors
1M ago
XENE
Xenon Strengthens Balance Sheet With Major Equity Offering
PremiumCompany Announcements
Xenon Strengthens Balance Sheet With Major Equity Offering
2M ago
8K
XENE
Xenon Pharmaceuticals 10.5M share Spot Secondary priced at $57.00
PremiumThe Fly
Xenon Pharmaceuticals 10.5M share Spot Secondary priced at $57.00
2M ago
XENE
Xenon Raises $650 Million in Upsized U.S. Equity Offering
PremiumCompany Announcements
Xenon Raises $650 Million in Upsized U.S. Equity Offering
2M ago
XENE
Xenon Pharmaceuticals: Buy Rating Backed by Superior X-TOLE2 Phase 3 Results and Commercial Upside for Azetukalner in Focal Epilepsy
PremiumRatings
Xenon Pharmaceuticals: Buy Rating Backed by Superior X-TOLE2 Phase 3 Results and Commercial Upside for Azetukalner in Focal Epilepsy
2M ago
XENE
Xenon Pharmaceuticals price target raised to $64 from $47 at Wedbush
PremiumThe FlyXenon Pharmaceuticals price target raised to $64 from $47 at Wedbush
2M ago
XENE
Xenon Pharmaceuticals price target raised to $90 from $60 at Guggenheim
Premium
The Fly
Xenon Pharmaceuticals price target raised to $90 from $60 at Guggenheim
2M ago
XENE
Xenon Pharmaceuticals price target raised to $68 from $49 at Wells Fargo
Premium
The Fly
Xenon Pharmaceuticals price target raised to $68 from $49 at Wells Fargo
2M ago
XENE
Biohaven price target raised to $27 from $24 at Goldman Sachs
PremiumThe Fly
Biohaven price target raised to $27 from $24 at Goldman Sachs
2M ago
BHVN
XENE
Xenon Pharmaceuticals price target raised to $75 from $52 at Goldman Sachs
PremiumThe Fly
Xenon Pharmaceuticals price target raised to $75 from $52 at Goldman Sachs
2M ago
XENE
Xenon Pharmaceuticals price target raised to $74 from $53 at H.C. Wainwright
PremiumThe Fly
Xenon Pharmaceuticals price target raised to $74 from $53 at H.C. Wainwright
2M ago
XENE
Xenon Pharmaceuticals price target raised to $90 from $56 at Deutsche Bank
PremiumThe Fly
Xenon Pharmaceuticals price target raised to $90 from $56 at Deutsche Bank
2M ago
XENE
Xenon Pharmaceuticals Launches $500 Million Public Share Offering
PremiumCompany AnnouncementsXenon Pharmaceuticals Launches $500 Million Public Share Offering
2M ago
XENE
Xenon Pharmaceuticals announces $500M common shares offering
Premium
The Fly
Xenon Pharmaceuticals announces $500M common shares offering
2M ago
XENE
Xenon Pharmaceuticals price target raised to $100 from $65 at Jefferies
Premium
The Fly
Xenon Pharmaceuticals price target raised to $100 from $65 at Jefferies
2M ago
XENE

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >